CAVU Biotherapies' Convertible Note Round

CAVU Biotherapies raised a round of funding on March 17, 2017.

CAVU Biotherapies is an early stage translational onco-biotech company focusing on providing immune-based solutions to treat cancer and autoimmune diseases. The company manufactures and develops adopt…

Articles about CAVU Biotherapies' Convertible Note Round: